Abivax Shares Struggle at the €100 Barrier
French biotech Abivax is up 2.11% at €99.15 in early afternoon trading, in a Paris market trending upwards. The SBF 120 is up 0.55% during the session. The stock maintains an exceptional annual performance, up over 1700%, despite a nearly 10% decline over the last three months.
A Stock Stuck Below its 20 and 50-Day Moving Averages After Quarterly Decline
The share price is below the 20-day moving average at €100.52 (a gap of -1.36%) and below the 50-day moving average at €100.81. These two close benchmarks form a short resistance zone that caps today's rebound. However, the 200-day moving average at €91.92 remains well below the current price, about 7.87% lower, indicating that the fundamental annual trend is still bullish despite recent consolidation.
The RSI at 45 is neutral, showing neither overselling nor a marked increase in buying interest. The technical support identified at €93.50 was preserved during the decline, and the next resistance is at €110.20, a level approached in early May following a $45 million ADS raise and the buyback of royalty certificates.
Net Short Positions Slightly Decrease, at 2.49% of Capital
According to reviewed statements, three funds hold a combined net short position representing 2.49% of the capital, with the latest declaration dated May 14, 2026. Over thirty days, this total has decreased by 0.32 points (from 2.81% a month earlier). This movement does not indicate a capitulation by short sellers, but it does suggest that some have reduced their bearish exposure on the stock. The level remains to be monitored without being overinterpreted in isolation.
The next technical threshold to watch remains the €100.52 - €100.81 zone, where the two short moving averages converge.
